Evotec Stock - analyst consensus stays cautious after delisting turmoil

Evotec stock remains under scrutiny as consensus expectations stay muted following its Xetra delisting and ongoing restructuring. On Monday, the focus for investors is on analyst targets, earnings expectations and how the biotech name now fits into the SDAX and TecDAX peer landscape.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/22/2026, 14:14 CET. Details in the imprint.

Evotec (DE0005664809) remains in a rebuilding phase after its 2024 governance and listing upheaval. With no fresh corporate news on Monday, analyst expectations and valuation metrics take center stage for the biotech stock.

What recent estimates show

Evotec stock attracts a mixed analyst view after last year's leadership changes and the temporary suspension of its shares, which unsettled parts of the market. Some houses have cut their price targets, while others highlight the company's broad partnering pipeline.

According to consensus data compiled by a German finance portal, the average target price for Evotec shares has been adjusted downward in recent months, reflecting more cautious growth and margin assumptions. Rating opinions range from Buy to Hold, with fewer outright Sell calls than during the immediate governance crisis.

How consensus frames the outlook

Analysts now tend to emphasize execution risks in Evotec's contract research and co-development model, especially around timelines for milestone and royalty streams. They also monitor cost discipline after the company's investment phase in biologics and gene-therapy capabilities.

On balance, consensus still expects Evotec to grow revenue faster than many traditional pharma names, but with softer profitability trajectories than pre-crisis guidance implied. Investors therefore focus closely on each upcoming quarterly report and any updates to mid-term targets.

How Evotec makes its money

Evotec generates revenue as a drug discovery and development partner for pharmaceutical and biotech companies, offering integrated research services, screening platforms and co-owned pipeline projects. Income stems from research fees, milestones and, in successful cases, future royalties on partnered compounds.

Where the stock trades today

The shares of Evotec (DE0005664809) trade on the Frankfurt venue at EUR 4.63 as of 06/19/2026, 17:35 CET.

Key facts on Evotec stock

• Company: Evotec SE
• ISIN: DE0005664809
• WKN: 566480
• Ticker: EVT
• Venue: Frankfurt
• Price (as of 06/19/2026, 17:35 CET): 4.63 EUR
• Market cap: 858,000,000 EUR (as of 06/19/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: SDAX, TecDAX
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.